Why the study?
Does F(ab')2 FRaMon safely inhibit platelet aggregation compared to abciximab in patients undergoing high-risk coronary angioplasty?
Does F(ab')2 FRaMon safely inhibit platelet aggregation compared to abciximab in patients undergoing high-risk coronary angioplasty?
F(ab')2 FRaMon bolus administration provides comparable platelet aggregation inhibition and safety to abciximab bolus plus infusion in high-risk coronary angioplasty.
Answers are grounded in this paper and cite their sources.
May support F(ab')2 FRaMon evaluation in angioplasty; leaves open efficacy versus abciximab in randomized trials.
The purpose of the study was to evaluate safety, effects on platelet aggregation and pharmacokinetics of F(ab')(2) fragments of anti-glycoprotein (GP) IIb-IIIa murine monoclonal antibody FRaMon (F(ab')(2) FRaMon) upon its intravenous administration in patients undergoing high-risk coronary angioplasty. Patients were treated before angioplasty with F(ab')(2) FRaMon at 0.2 mg/kg (n = 17) and 0.25 mg/kg (n = 12) bolus or with abciximab at 0.25 mg/kg bolus + 12 h infusion at 0.125 microg/kg per min (n = 29). F(ab')(2) FRaMon at both doses decreased platelet aggregation induced by 20 microM ADP to <10, <20, <40 and <70% of the predrug level at 1, 12, 24 and 72 h after injection, respectively. No significant differences were observed between F(ab')(2) FRaMon and abciximab antiaggregatory effects. In none of the patients did F(ab')(2) FRaMon cause allergic reactions, major bleedings or deep thrombocytopenia. Antibodies against F(ab')(2) FRaMon were detected in one patient. Free F(ab')(2) FRaMon was cleared from plasma within 12 h, while platelet-bound preparation occupied >95, 70-80 and 40-50% of GP IIb-IIIa at 1 and 12-24 h and 3 days after injection, respectively. Thrombotic complications within the first month after angioplasty in groups treated with F(ab')(2) FRaMon and abciximab were observed in one and two patients, respectively. The data obtained have shown that F(ab')(2) FRaMon at bolus administration to patients undergoing coronary angioplasty caused no serious side effects and at comparative dosage inhibited platelet aggregation with the same efficacy as abciximab at bolus + infusion administration.
No takes yet. Share an insight, caveat, or question.
Мазуров et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: